𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

✍ Scribed by Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; Aynur Feyzioglu; Dilek Ince Gunal; Gorsev G. Yener; Raif Cakmur; Huseyin A. Sahin; Murat Emre

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
113 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving stable dopaminergic treatment were assigned to receive rasagiline 1 mg/day or placebo for 3 months. Patients were eligible if they had impairment in 2 of 4 cognitive domains (attention, executive functions, memory, visuospatial functions) in the screening neuropsychological tests, yet did not fulfill criteria for Parkinson's disease dementia. Fifty‐five patients were randomized; 48 patients completed the study. Patients in the rasagiline group showed significant improvement in digit span–backward compared with the placebo group (P = .04), with trends favoring rasagiline in digit span total and digit‐ordering tests. Verbal fluency total score showed a significant difference in favor of rasagiline (P = .038), with trends favoring rasagiline in semantic fluency test and Stroop spontaneous corrections. The composite cognitive domain Z scores revealed a significant difference in favor of rasagiline compared with placebo in the attentional Z score (P < .005). There were no significant differences between the 2 groups in the other cognitive tests or cognitive domain Z scores. The monoamine oxidase type‐B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson's disease with cognitive impairment. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau

The impact of left prefrontal repetitive
The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study
✍ Endre Pal; Ferenc Nagy; Zsuzsanna Aschermann; Eva Balazs; Norbert Kovacs 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract Based on several open‐label and case studies, repetitive transcranial magnetic stimulation (rTMS) seems to have an antidepressive effect on patients with Parkinson's disease (PD). However, this hypothesis requires further confirmation. We conducted a randomized, double‐blind placebo‐con

Safety of entacapone and apomorphine coa
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic

Ciprofloxacin or metronidazole for the t
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study
✍ Kelvin T. Thia; Uma Mahadevan; Brian G. Feagan; Cindy Wong; Alan Cockeram; Alain 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background: Although metronidazole and ciprofloxacin are used to treat perianal Crohn's disease (CD), no placebo-controlled trials have been performed. ## Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of metronidazole and ciprofloxacin in patients with

The effect of injecting botulinum toxin
The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo-controlled pilot study
✍ Tanya Gurevich; Chava Peretz; Orna Moore; Nina Weizmann; Nir Giladi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

## Abstract ## Objective To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. ## Method BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assess